Skip to main content
Equibles
STOK logo

STOK · Stoke Therapeutics, Inc.

Track STOK — free

Use STOK with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about STOK

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$32.32 +0.92 (+2.93%) At close · Aug 21
Market Cap
$1.99B
Shares
64.53M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$31.40 Open$32.48 Day$29.86–32.59 52W close$18.87–38.35 Avg vol 30d787K Short int15.8M · 24.5% float · 27.7d Short vol70% Last earningsAug 3, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 3

Up next

Next earnings call
Oct 28, 2026 Est · unconfirmed · in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 3, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Buy Momentum Weak Sentiment Bearish Fundamentals Excellent Quant / Vol Very High
      Market backdrop VIX 16 · calm Equity put/call 0.58
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg −1%
      below
      Price vs 50-day avg +2%
      above
      RSI (14) 51
      neutral
      MACD trend Positive
      52-week position 64%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Weak
      1-month return +6%
      trailing
      6-month return −14%
      trailing
      YTD return −1%
      this year
      Relative strength −25%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bearish
      Trend (MA cross) No cross
      50d $31 › 200d $32 — 200d above 50d
      Institutional flow Distributing
      -1% holders QoQ · +31 funds added
      Insider flow Distributing
      Net -$646.9K over 90 days · 100% sells
      Short interest Rising
      24.50% of float · ▲ +0.7% MoM · 27.7 days cover
      Volume signal Reversal watch
      High volume on a down day — possible exhaustion
      Institution breadth Multi-yr high
      197 holders — near 3-yr high, broad support
      Squeeze score 71
      high risk · 0–100
      Fundamentals
      Excellent
      Revenue growth +405%
      Y/Y
      EPS growth +93%
      Y/Y
      Free cash flow $44.9M
      Balance sheet $84.2M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 59%
      annualized · 1-yr
      Max drawdown −37%
      past year
      ATR 5.3%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Buy
      0 · 5 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −1% Neutral
      Price vs 50-day avg
      +2% Bullish
      RSI (14)
      51 Neutral
      MACD trend
      Positive Bullish
      52-week position
      64% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bearish · 3 of 6
      Trend (MA cross) No cross
      50d $31 › 200d $32 — 200d above 50d
      Institutional flow Distributing
      -1% holders QoQ · +31 funds added
      Insider flow Distributing
      Net -$646.9K over 90 days · 100% sells
      Short interest Rising
      24.50% of float · ▲ +0.7% MoM · 27.7 days cover
      Volume signal Reversal watch
      High volume on a down day — possible exhaustion
      Institution breadth Multi-yr high
      197 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $19 Now $31 · 64% Range high $38
      vs 200-day avg -1% vs 50-day avg +2%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      additional cohort of patients being enrolled in Europe 30 Q2 2026 —
      completion of enrollment of 162 patients in the U.S., UK and Japan 162 Q2 2026 —
      patients through Week 24 80 as of July 31, 2026 —
      patients through Week 28 60 as of July 31, 2026 —
      patients through Week 8 145 as of July 31, 2026 —
      Activated sites in Europe for Phase 3 EMPEROR study 15 Phase 3 EMPEROR study, Europe (Germany, France, Spain and Italy) —
      Active sites for Phase 1 OSPREY study 7 Phase 1 OSPREY study —
      Additional patients being screened in Europe 20 Phase 3 EMPEROR study, Europe (Germany, France, Spain and Italy) —
      Doses administered in Phase 1/2a and OLE studies 850 Phase 1/2a and ongoing OLE studies —
      Patients continued treatment in OLE studies 93% Phase 1/2a OLE studies —
      Patients randomized in Phase 3 EMPEROR study 130 As of May 5, Phase 3 EMPEROR study —
      Patients remained in OLE studies at 4-year data cutoff 77% 4-year data cutoff, OLE studies —
      Patients with elevated CSF protein classified as treatment-emergent adverse event 59% Phase 1/2a and OLE studies —
      Patients with elevated CSF protein lab values 94% Phase 1/2a and OLE studies —
      Planned enrollment in Phase 3 EMPEROR study 150 Phase 3 EMPEROR study —
      Total sites in Europe for Phase 3 EMPEROR study 16 Phase 3 EMPEROR study, Europe (Germany, France, Spain and Italy) —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      STOK
      Stoke Therapeutics, Inc.
      this stock
      		$1.99B -1.1% +404.5% — 24.5%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $136.93B +19.2% +46.2% 31.5 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $86.39B +7.1% +20.8% 20.8 3.3%
      ARGX
      Argenx SE
      		 $64.56B +23.4% — — 2.1%
      CSLLY
      Csl Ltd
      		 $58.31B — — — 0.0%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      197
      % held
      118.2%
      Net QoQ
      +4.8M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      242
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      15.8M
      Days to cover
      27.7d
      Change
      +117.1K sh
      View
      Short Volume
      Short vol %
      70%
      As of
      Aug 21, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      1.2K
      Value
      $34.7K
      As of
      Jul 24, 2026
      View
      Off-Exchange
      Off-exchange %
      39.6%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$646.9K
      Buyers / Sellers
      0 / 3
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $184.4M
      Net income (FY)
      $-6.9M
      EPS diluted
      $-0.12
      View
      Filings
      SEC Filings
      Latest
      Investor Event Transcript
      Filed
      Aug 12, 2026
      This year
      17
      View
      Proposed Sales
      Value
      $605.1K
      Shares
      21.0K
      Filed
      Aug 3, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 12, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      STOK +0.3% +5.9% -13.8% +8.8% -1.1%
      SPY -2.0% +3.3% +11.2% +2.1% +11.8%
      vs SPY +2.3% +2.6% -24.9% +6.7% -12.9%
      Key facts CIK 1623526 CUSIP 86150R107 13F (30d) 188 filings 184 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)